December 28, 2018 – Vancouver, British Columbia – In response to the recent passage of the 2018 U.S. Farm Bill, Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQB: FFRMF) is pleased to announce that it is expanding its existing hemp portfolio to include a potential partnership in Florida. The Florida project builds on Future Farm’s work with its partner, Rahan Meristem, Ltd., to apply molecular and analytical tools for the discovery of scientifically recognized medicinal and industrial uses of hemp-derived products.

The wealth of cannabinoids and terpenes in hemp opens a wide window of opportunities for expansion of endorsed medical uses of hemp products. Currently, Future Farm is a finalist among seven potential research partners being considered by Florida A&M University, which is preparing to commence industrial hemp research and production.

Passage of the 2018 U.S. Farm Bill serves to ratify the Company’s drug discovery work and will facilitate market entry with new products that may soon be endorsed by regulators. Legalization of hemp will also allow comprehensive research relating to hemp and, specifically, cannabidiol (CBD). Future Farm will distinguish itself as an industry leader by conducting federally recognized, longitudinal studies employing the strictest of scientific standards.

“The significance of this legislation cannot be understated as it paves the way for the industry to expand, while providing legitimacy at the governmental and institutional levels,” states Jim Cincotta, Future Farm’s manager of its Florida operations. “It will allow for in-depth exploration of the myriad of applications of this remarkable plant. We know that some of the Florida based research activities will explore optimal hemp growing conditions to assure a consistent supply for local medicinal, retail and industrial processors.”

Future Farm’s team of experts is equipped to associate specific molecular profiles with pharmaceutical uses and its team of researchers is comprised of domain experts in analytical chemistry, tissue and cell biology, pharmacology and horticulture. The Company’s aim is to develop health related products in order to augment the commercial value of a variety of hemp compounds.

For further information, contact Investor Relations at investor@futurefarmtech.com or (888) 387-3761, Ext. 710.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, Chairman and CEO

Tagged with →